Clinical trial

Effect of Combined Vitamin C, Stress-dose Steroids, and Thiamine on Cerebral Autoregulation and Functional Outcomes of Patients With Septic Shock

Name
163-10-5-2018
Description
This study has been approved as a nested substudy of a multicenter trial (CORVICTES, Clinicaltrials.gov Identifier: NCT03592693). The current, randomized, placebo-controlled study will compare steroids/vitamin C versus placebo/placebo in septic shock, with respect to cerebral autoregulation, biomarkers, and functional outcome. The following hypotheses will be tested: The steroids/vitamin C/thiamine intervention may result in attenuation of the septic shock-associated impairment in cerebral autoregulation; and 2) The increased frequency of intact cerebral autoregulation in the intervention group may result in more neurologic failure free days and ventilator free days during a 60-day follow-up; improved survival to hospital discharge with good functional outcome; and better patient-reported health-related outcomes at 90-day follow-up.
Trial arms
Trial start
2018-09-06
Estimated PCD
2025-05-01
Trial end
2025-05-01
Status
Recruiting
Phase
Early phase I
Treatment
Stress-dose Hydrocortisone plus Vitamin C
Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Arms:
Steroids/Vitamin C group
Other names:
Vitamin-Steroid
isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo
Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
Arms:
Control group
Other names:
Placebo-placebo
Size
100
Primary endpoint
Cerebral autoregulation
24-78 hours after randomization
Cerebral blood flow
24-78 hours after randomization
Eligibility criteria
Inclusion Criteria: • Diagnosis of septic shock within 12 hours of admission to the intensive care unit (ICU). Exclusion Criteria: * Age \< 18 years * Pregnancy * Patients with a fatal underlying disease who are unlikely to survive to hospital discharge * Patients with acquired immunodeficiency and a CD4 count of \< 50 / μL * Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency. * Patients with sepsis/septic shock transferred from another hospital * Patients with features of sepsis/septic shock \> 12 hours * Patients who require treatment with corticosteroids for an indication other than sepsis * Patients with any history of an allergic reaction
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Single-center, prospective, randomized, doubleblind, placebo-controlled, parallel-group clinical trial.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Participant, Care Provider, Investigator, Outcomes Assessor', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-05-10

1 organization

2 products

1 indication

Indication
Septic shock